{'52WeekChange': 1.2592001,
 'SandP52WeekChange': 0.0644362,
 'address1': 'West Tower, OmniVision',
 'address2': 'Suite 802 88 Shangke Road Pudong District',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 30.3,
 'askSize': 1200,
 'averageDailyVolume10Day': 49700,
 'averageVolume': 59671,
 'averageVolume10days': 49700,
 'beta': None,
 'beta3Year': None,
 'bid': 28.05,
 'bidSize': 800,
 'bookValue': None,
 'category': None,
 'circulatingSupply': None,
 'city': 'Shanghai',
 'companyOfficers': [],
 'country': 'China',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 29.5,
 'dayLow': 27.91,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': None,
 'enterpriseToRevenue': None,
 'enterpriseValue': 1730821248,
 'exDividendDate': None,
 'exchange': 'NGM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 29.111143,
 'fiftyTwoWeekHigh': 35,
 'fiftyTwoWeekLow': 9.3,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 23104411,
 'forwardEps': None,
 'forwardPE': None,
 'fromCurrency': None,
 'fullTimeEmployees': 185,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.00986,
 'heldPercentInstitutions': 0.00921,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/i-mabbiopharma.com',
 'longBusinessSummary': 'I-Mab, a clinical stage biopharmaceutical company, '
                        'engages in the discovery, development, and '
                        'commercialization of novel or highly differentiated '
                        'biologics to treat diseases with unmet medical needs, '
                        'primarily cancers and autoimmune disorders worldwide. '
                        'It is developing TJ202, a CD38 antibody in Phase III '
                        'clinical trials to treat multiple myeloma and '
                        'autoimmune diseases; TJ101, a long-acting human '
                        'growth hormone that is in Phase II clinical trials to '
                        'treat pediatric growth hormone deficiency; and TJ301, '
                        'a IL-6 blocker in Phase II clinical trials for the '
                        'treatment of ulcerative colitis and other autoimmune '
                        "diseases. The company's product candidates in Phase I "
                        'clinical trials include Enoblituzumab, a humanized '
                        'B7-H3 antibody to treat immuno-oncology; TJ107, a '
                        'long-acting recombinant human IL-7 to treat cancer '
                        'treatment-related lymphopenia and cancer '
                        'immunotherapy; TJC4, a CD47 monoclonal antibody with '
                        'RBC-sparing differentiation; TJD5, a CD73 antibody '
                        'for cancer treatment; and TJM2, a GM-CSF monoclonal '
                        'antibody for rheumatoid arthritis and CAR-T-related '
                        'therapies. Its product candidates in pre-clinical '
                        'development comprise TJ210, an antibody targeting '
                        'myeloid derived suppressor cells in cancers and '
                        'autoimmune diseases; and TJX7, a novel CXCL13 '
                        'antibody for autoimmune diseases. The company was '
                        'founded in 2014 and is headquartered in Shanghai, the '
                        "People's Republic of China.",
 'longName': 'I-Mab',
 'market': 'us_market',
 'marketCap': 1633090944,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_642067965',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1577750400,
 'navPrice': None,
 'netIncomeToCommon': None,
 'nextFiscalYearEnd': 1640908800,
 'open': 29.01,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '86 21 6057 8000',
 'previousClose': 29.82,
 'priceHint': 2,
 'priceToBook': None,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 29.5,
 'regularMarketDayLow': 27.91,
 'regularMarketOpen': 29.01,
 'regularMarketPreviousClose': 29.82,
 'regularMarketPrice': 29.01,
 'regularMarketVolume': 49982,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 57829000,
 'sharesPercentSharesOut': 0.0013,
 'sharesShort': 18672,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 9080,
 'shortName': 'I-MAB',
 'shortPercentOfFloat': None,
 'shortRatio': 1.42,
 'startDate': None,
 'strikePrice': None,
 'symbol': 'IMAB',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': None,
 'twoHundredDayAverage': 18.725367,
 'volume': 49982,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.i-mabbiopharma.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '201210'}